Delving into the Latest Updates on Mesenchymal Stem Cells(Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Fracture, segmental

Originator Organization

The National Academy of Sciences of Belarus

Active Organization-

Inactive Organization

The National Academy of Sciences of Belarus

License Organization-

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDCOVID-19 (coronavirus disease 2019) is a pandemic around the world, and its treatment options often fail to achieve ideal results. There is a lot of controversy in the treatment of COVID-19 with mesenchymal stem cells (MSCs). The study aims to assess the safety and efficacy of mesenchymal treatment of new coronary pneumonia.METHODSWe manually searched electronic databases including PubMed, Embase, Cochrane Library, and Web of Science until 25th July 2022, and Stata 15.0 (StataCorpLLC: College Station, TX, USA) was used to analyze the data.RESULTSA total of 8 randomized controlled trials were included, involving a total of 345 people, of which 180 were in the MSCs group and 165 were in the placebo group. The analysis results showed that MSCs can reduce mortality in COVID-19 patients compared to placebo [RR (Risk Ratio) = 0.56, 95% CI (Confidence Interval) (0.36, 0.89); p = 0.003]. There was no significant difference between the mesenchymal stem cell group and the placebo group in the incidence of adverse reactions [RR = 0.64, 95% CI (0.34, 1.18); p = 0.281]; In the SpO₂/FiO₂ (Oxygen Saturation/Fraction of Inspiration O₂) [WMD (Weighted Mean Difference) = 9.07, 95% CI (-38.01, 56.15); p = 0.080]; In ICU (Intensive Care Unit) stay [WMD = -1.66, 95% CI (-7.23, 3.91); p = 0.131].CONCLUSIONSMesenchymal stem cells can reduce the mortality of COVID-19 patients.

01 Jun 2013·ChestQ1 · MEDICINE

A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD

Q1 · MEDICINE

Article

Author: Weiss, Daniel J ; Casaburi, Richard ; LeRoux-Williams, Michelle ; Tashkin, Donald P ; Flannery, Robin

BACKGROUNDCOPD is a devastating disease affecting millions worldwide. As disease pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory effects of systemically administered mesenchymal stem cells (MSCs) may decrease inflammation, resulting in improved lung function and quality of life. The goal of this study was to assess safety and to perform an initial evaluation of the potential efficacy of systemic MSC administration to patients with moderate to severe COPD.METHODSSixty-two patients at six sites were randomized to double-blinded IV infusions of either allogeneic MSCs (Prochymal; Osiris Therapeutics Inc) or vehicle control. Patients received four monthly infusions (100 × 10⁶ cells/infusion) and were subsequently followed for 2 years after the first infusion. End points included comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, 6MWT, and assessments of systemic inflammation.RESULTSAll study patients completed the full infusion protocol, and 74% completed the 2-year follow-up. There were no infusional toxicities and no deaths or serious adverse events deemed related to MSC administration. There were no significant differences in the overall number of adverse events, frequency of COPD exacerbations, or worsening of disease in patients treated with MSCs. There were no significant differences in PFTs or quality-of-life indicators; however, an early, significant decrease in levels of circulating C-reactive protein (CRP) was observed in patients treated with MSCs who had elevated CRP levels at study entry.CONCLUSIONSSystemic MSC administration appears to be safe in patients with moderate to severe COPD and provides a basis for subsequent cell therapy investigations.TRIAL REGISTRYClinicalTrials.gov; No.: NCT00683722; URL: www.clinicaltrials.gov.

Journal of Korean Medical ScienceQ4 · MEDICINE

Therapeutic Effects of Mesenchymal Stem Cells on a Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Model

Q4 · MEDICINE

ArticleOA

Author: Kim, Tae-Bum ; Song, Woo-Jung ; Kim, Jung-Hyun ; Oh, In Young ; Cho, You Sook ; Kwon, Hyouk-Soo ; Kim, Hyo-Jung ; Seo, Bomi ; Park, So-Young ; Moon, Hee-Bom ; Kwon, Oh Young

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are the most severe cutaneous drug hypersensitivity reactions, which are unpredictable adverse drug reactions. SJS/TEN is associated with significant mortality and morbidity; however, effective treatment is difficult. Mesenchymal stem cells (MSCs) are well-known for their anti-inflammatory and tissue regeneration properties. The purpose of the present study was to verify whether MSCs could be applied for the treatment of SJS/TEN. We developed an SJS/TEN mouse model using peripheral blood mononuclear cells from a lamotrigine-induced SJS patient. MSCs were injected into the model to verify the treatment effect. In SJS model mice treated with MSCs, ocular damage rarely occurred, and apoptosis rate was significantly lower. We demonstrated a therapeutic effect of MSCs on SJS/TEN, with these cells presenting a potential novel therapy for the management of this disorder.

100 Deals associated with Mesenchymal Stem Cells(Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus)

Login to view more data